MacroGenics, Inc. (MGNX) is a clinical-stage biopharmaceutical company developing antibody-based cancer treatments. Among its coverage, three recent price targets identify both the firm and the analyst. B. Riley Securities (Mayank Mamtani) carries the highest target at $11 after raising it from $9 in August 2026 and upgrading the stock to Buy from Neutral earlier in the year. Barclays (Etzer Darout) holds an Overweight rating with a $6 target, up from $4. Stifel (Stephen Willey) sits at the cautious end with a Hold rating and a $4 target.
The arithmetic mean of these three targets is $7.00, rounded to a central target of $7. The $4-to-$11 range is unusually wide — a sign that analysts disagree fundamentally about the probability of success for the pipeline. Several other firms (H.C. Wainwright and TD Cowen) rate the stock Hold but do not currently publish a numerical target, so they are excluded from the calculation. No single analyst's view is being treated as more likely than another's.
Shares closed near $3.33 in mid-October 2026, giving the company a market value of roughly $207 million — squarely in micro-cap territory. The 52-week range spans $1.29 to $5.08. Because the $7 central target sits about 110% above the current price, the implied move is very large by any standard and would require the stock to trade well beyond its 52-week high.
That path likely runs through clinical data rather than near-term earnings. MacroGenics' commercial product, MARGENZA (margetuximab), is approved for HER2-positive metastatic breast cancer, but the investment case now centers on the investigational bispecific antibody lorigerlimab (targeting PD-1 and CTLA-4) and two ADCs, MGC026 and MGC028. In its most recent quarterly report, the company posted revenue of roughly $32.8 million, well below analyst estimates near $68.8 million, alongside a wider-than-expected net loss — a reminder that the stock remains event-driven and volatile.
MacroGenics shares have pulled back from the October range above $3.70 and currently trade below their 50-day and 200-day moving averages. The 52-week high near $5.08 marks a meaningful resistance zone and a psychological $5 level sits just beneath it. Near-term support appears around $3.20–$3.25, with the 52-week low near $1.29 representing the outer downside reference. A sustained move toward the $7 target would first require reclaiming the $5 area — a roughly 50% advance on its own.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual analysts apply different assumptions. Because MGNX is a clinical-stage name, the calendar is driven by data events rather than quarterly earnings alone. Investors should watch for LORIKEET and LINNET results, MGC026 and MGC028 data updates, the next earnings report (estimated around mid-November 2026), any financing or partnership announcements, and further analyst rating or target revisions. Cash balance and operating-expense trends are equally important given the liquidity questions surrounding the company.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover new opportunities, keep tabs on existing positions, and identify shifting trends more efficiently than manual screening. For investors tracking volatile, event-driven names like MacroGenics, an automated signal layer can add a useful, real-time perspective alongside fundamental research.
The $7 central target reflects the average of three verified analyst targets — $4, $6, and $11 — and sits roughly 110% above the current share price, making it a very large implied move. The bull case rests on the oncology pipeline, particularly lorigerlimab and the two ADC candidates, supported by recent upgrades from B. Riley and Barclays. The bear case centers on persistent losses, a recent revenue miss, and a thin, cash-constrained balance sheet, with Stifel's $4 target embodying that caution. The unusually wide analyst range signals genuine uncertainty rather than a settled view. Whether MGNX can reach $7 will most likely be decided by clinical data and financing decisions, not near-term earnings — and no outcome is assured.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with KRRO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then KRRO could also see price increases.
| Ticker / NAME | Correlation To MGNX | 1D Price Change % | ||
|---|---|---|---|---|
| MGNX | 100% | +1.11% | ||
| KRRO - MGNX | 45% Loosely correlated | +29.71% | ||
| VYGR - MGNX | 44% Loosely correlated | -7.92% | ||
| AMRN - MGNX | 44% Loosely correlated | +0.78% | ||
| ZVRA - MGNX | 41% Loosely correlated | -0.29% | ||
| MLTX - MGNX | 34% Loosely correlated | +15.87% | ||
More | ||||